Full Press Release Details
ADC Therapeutics to Present at the Jefferies
Healthcare Conference
LAUSANNE, Switzerland, June 1, 2022 -
ADC Therapeutics SA (NYSE: ADCT) announced today that its Chief Executive Officer, Ameet Mallik, will be participating in a fireside chat
at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 9:00 am ET.
A live webcast of the presentation will be available
via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com.
A replay of the webcast will be available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs).
The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies
ADC Therapeutics' CD19-directed ADC ZYNLONTA
(loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being
evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced
solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biop le),
Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/
and follow the Company on Twitter and LinkedIn.
ZYNLONTA is a registered trademark of ADC Therapeutics